BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26456240)

  • 21. Dual-responsive mPEG-PLGA-PGlu hybrid-core nanoparticles with a high drug loading to reverse the multidrug resistance of breast cancer: an in vitro and in vivo evaluation.
    Xu H; Yang D; Cai C; Gou J; Zhang Y; Wang L; Zhong H; Tang X
    Acta Biomater; 2015 Apr; 16():156-68. PubMed ID: 25662165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversal of doxorubicin resistance by guggulsterone of Commiphora mukul in vivo.
    Xu HB; Shen ZL; Fu J; Xu LZ
    Phytomedicine; 2014 Sep; 21(11):1221-9. PubMed ID: 25172783
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of 5-azacytidine on miRNA expression in human breast cancer cells with different sensitivity to cytostatics.
    Chekhun VF; Borikun TV; Lukianova NY
    Exp Oncol; 2016 Mar; 38(1):26-30. PubMed ID: 27031715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medicarpin and millepurpan, two flavonoids isolated from Medicago sativa, induce apoptosis and overcome multidrug resistance in leukemia P388 cells.
    Gatouillat G; Magid AA; Bertin E; El btaouri H; Morjani H; Lavaud C; Madoulet C
    Phytomedicine; 2015 Dec; 22(13):1186-94. PubMed ID: 26598918
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.
    Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS
    Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development and characterization of P-glycoprotein 1 (Pgp1, ABCB1)-mediated doxorubicin-resistant PLHC-1 hepatoma fish cell line.
    Zaja R; Caminada D; Loncar J; Fent K; Smital T
    Toxicol Appl Pharmacol; 2008 Mar; 227(2):207-18. PubMed ID: 18076962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoparticle-directed sub-cellular localization of doxorubicin and the sensitization breast cancer cells by circumventing GST-mediated drug resistance.
    Zeng X; Morgenstern R; Nyström AM
    Biomaterials; 2014 Jan; 35(4):1227-39. PubMed ID: 24210875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.
    Shen J; He Q; Gao Y; Shi J; Li Y
    Nanoscale; 2011 Oct; 3(10):4314-22. PubMed ID: 21892492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells.
    Zhong Y; Yang W; Sun H; Cheng R; Meng F; Deng C; Zhong Z
    Biomacromolecules; 2013 Oct; 14(10):3723-30. PubMed ID: 23998942
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
    Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
    Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Active Drug Targeting of a Folate-Based Cyclodextrin-Doxorubicin Conjugate and the Cytotoxic Effect on Drug-Resistant Mammary Tumor Cells In Vitro.
    Mizusako H; Tagami T; Hattori K; Ozeki T
    J Pharm Sci; 2015 Sep; 104(9):2934-40. PubMed ID: 25940848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acid-Sensitive Peptide-Conjugated Doxorubicin Mediates the Lysosomal Pathway of Apoptosis and Reverses Drug Resistance in Breast Cancer.
    Sheng Y; Xu J; You Y; Xu F; Chen Y
    Mol Pharm; 2015 Jul; 12(7):2217-28. PubMed ID: 26035464
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of adriamycin-induced cytotoxicity by increasing retention and inhibition of DNA repair in DOX-resistant P388 cell lines with new calcium channel blocker, DMDP.
    Bankusli I; Yin MB; Mazzoni A; Abdellah AJ; Rustum YM
    Anticancer Res; 1989; 9(3):567-74. PubMed ID: 2764503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Doxorubicin-loaded silicon nanowires for the treatment of drug-resistant cancer cells.
    Peng F; Su Y; Ji X; Zhong Y; Wei X; He Y
    Biomaterials; 2014 Jun; 35(19):5188-95. PubMed ID: 24702959
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nuclear targeting and nuclear retention of anthracycline-formaldehyde conjugates implicates DNA covalent bonding in the cytotoxic mechanism of anthracyclines.
    Taatjes DJ; Fenick DJ; Koch TH
    Chem Res Toxicol; 1999 Jul; 12(7):588-96. PubMed ID: 10409398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
    Tapiero H; Nguyen-Ba G; Lampidis TJ
    Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oestrogen treatment enhances the sensitivity of hormone-resistant breast cancer cells to doxorubicin.
    Scherbakov AM; Lobanova YS; Andreeva OE; Shatskaya VA; Krasil'nikov MA
    Biosci Rep; 2011 Apr; 31(2):137-43. PubMed ID: 20662767
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sensitivity of multidrug-resistant MCF-7 cells to a transferrin-doxorubicin conjugate.
    Lemieux P; Pagé M
    Anticancer Res; 1994; 14(2A):397-403. PubMed ID: 8017839
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
    Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
    Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.